

Erratum to: Clinical findings on ANCA-associated renal vasculitis from the Japan RPGN registry obtained via a questionnaire survey

Kunihiro Yamagata · Joichi Usui · Hitoshi Sugiyama ·
Kosaku Nitta · Takashi Wada · Eri Muso · Yoshihiro Arimura ·
Akio Koyama · Hirofumi Makino · Seiichi Matsuo

Published online: 23 March 2013
© Japanese Society of Nephrology 2013

Erratum to: Clin Exp Nephrol
DOI 10.1007/s10157-012-0740-1

Table 2 and Fig. 2 appeared incorrectly in the article cited above. They are correctly shown as follows.

The online version of the original article can be found under doi:10.1007/s10157-012-0740-1.

K. Yamagata (✉) · J. Usui
Department of Nephrology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
e-mail: kidney@md.tsukuba.ac.jp

J. Usui
e-mail: j-usui@md.tsukuba.ac.jp

H. Sugiyama · H. Makino
Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

K. Nitta
Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan

T. Wada
Division of Nephrology, Kanazawa University Hospital, Kanazawa, Japan

Table 2 The clinical grading system for predicting RPGN patient prognosis [1]

Clinical score	Serum creatinine (mg/dl)	Age (years old)	Lung involvement	Serum CRP (mg/dl)
0	<3	≤59	Negative	<2.6
1	3–6	60–69		2.6–10.0
2	≥6	≥70	Positive	>10.0
3	Dialysis			

Clinical grade	
I	0–2
II	3–5
III	6–7
IV	8–9


E. Muso
Department of Nephrology and Dialysis, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan

Y. Arimura
First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

A. Koyama
Department of Nephrology, Tsukuba Memorial Hospital, Tsukuba, Ibaraki, Japan

S. Matsuo
Department of Nephrology, Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

Fig. 2 Treatment algorithm for ANCA-associated RPGN in Japan [2]. *ESRD* end-stage renal disease, *OCS* oral corticosteroid, *MP* methylprednisolone, *PSL* prednisolone, *CYC* cyclophosphamide, *IVCYC* intravenous cyclophosphamide



*Older patients often suffered from opportunistic infection. Milder treatment (less dose of PSL, without MP or CYC) were recommended.